We have identified a list of several trending healthtech stocks that appear have recently received buy ratings from top Wall Street analysts and are showing positive investor sentiment, as well as news headlines. With that said, our editors here at healthtechmovers.com, are adding these healthtech companies to our watchlist to see if this momentum continues. Our watchlist includes trending
Summary: MoonLake Immunotherapeutics AG is a clinical-stage biotechnology company. It focused on creating next-level therapies for inflammatory skin and joint diseases. MoonLake Immunotherapeutics AG, formerly known as Helix Acquisition Corp., is based in BOSTON.
- Recent MLTX Stock Price: $57.40
- Yearly Gain for MLTX stock: 620.50%
- Market Cap for MLTX stock: $3.08B
- P/E Ratio for MLTX stock: -55.337
Will MLTX's stock price go up? Is there an accurate MLTX stock forecast available?
TipRanks.com reports that MoonLake Immunotherapeutics currently has 5 analysts offering 12-month price targets and the consensus is a Strong Buy rating with an average price target is $71.80. The target pricing ranges from a high MLTX forecast of $86 down to a low forecast of $60. MoonLake Immunotherapeutics (MLTX)’s last closing stock price was $57.40 which would put the average price target at 21.95% upside.
In addition, TradingView issued a buy rating for MLTX stock over the next month, Barchart.com has a Strong buy rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on MLTX stock.
Other analysts covering MLTX include:
- Andreas Argyrides of Wedbush issued a Buy rating with the price target of $86 on 1 day ago
- Thomas Smith of SVB Securities issued a Buy rating with the price target of $70 on 2 days ago
- Rami Katkhuda of LifeSci Capital issued a Buy rating with the price target of $75 on 2 days ago
- Julian Harrison of BTIG issued a Buy rating with the price target of $68 on 2 days ago
If you are wondering if MLTX is a good stock to buy, here are 3rd party ratings for MLTX stock:
- TipRanks.com: Strong Buy
- TradingView.com: buy
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: Strong buy
- Zacks.com: Hold, Top 40% (101 out of 252)
What is the sentiment on the street regarding MoonLake Immunotherapeutics? (Current ratings compiled by TipRanks.com)
- News Sentiment for MLTX stock: Very Bullish
- Blogger Consensus for MLTX stock: Bullish
- Media Buzz for MLTX stock: Medium
- Insider Signal for MLTX stock: Positive
- Investor Sentiment for MLTX stock: Very Positive
- Hedge Fund signal for MLTX stock: Neutral
The stock market is extremely volatile, and you need to do your own research on MLTX stock including scouring the social networks like MLTX StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for MLTX stock chart >>
Summary: BioMarin Pharmaceutical Inc. focuses on the development and commercialization of treatments for serious life-threatening medical conditions, mostly for children. The company's portfolio comprises seven marketed products namely, Aldurazyme, Naglazyme, Kuvan a rare genetic enzyme deficiency disorder), Vimizim , Brineura, Palynziq and Voxzogo. BioMarin has a collaboration agreement with Sanofi's subsidiary Genzyme for Aldurazyme. Genzyme is BioMarin's sole customer for Aldurazyme and is responsible for marketing and selling Aldurazyme to third parties.'The newest drug in BioMarin's portfolio, Voxzogo for treating achondroplasia, the most common form of dwarfism. BioMarin's biologics license application (BLA) for Roctavian/valoctocogene roxaparvovec (valrox), a gene therapy for severe hemophilia A, was given a complete response letter (CRL) by the FDA.
- Recent BMRN Stock Price: $87.68
- Yearly Gain for BMRN stock: 5.48%
- Market Cap for BMRN stock: $17.24B
- P/E Ratio for BMRN stock: 177.351
Will BMRN's stock price go up? Is there an accurate BMRN stock forecast available?
TipRanks.com reports that BioMarin Pharmaceutical currently has 4 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $99.50. The target pricing ranges from a high BMRN forecast of $95 down to a low forecast of $100. BioMarin Pharmaceutical (BMRN)’s last closing stock price was $87.68 which would put the average price target at 30.78% upside.
In addition, TradingView issued a Strong sell rating for BMRN stock over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Bullish short-term outlook. Remember, securities are volatile, so please do your own research on BMRN stock.
Other analysts covering BMRN include:
- Christopher Raymond of Piper Sandler issued a Buy rating with the price target of $125 on 1 day ago
- Luca Issi of RBC Capital issued a Hold rating with the price target of $100 on 1 day ago
- George Farmer of Scotiabank issued a Hold rating with the price target of $95 on 1 day ago
If you are wondering if BMRN is a good stock to buy, here are 3rd party ratings for BMRN stock:
- TipRanks.com: Moderate Buy
- TradingView.com: Strong sell
- Yahoo! Finance: Bullish Short-Term Outlook
- Barchart.com: sell
- Zacks.com: Hold, Top 40% (101 out of 252)
What is the sentiment on the street regarding BioMarin Pharmaceutical? (Current ratings compiled by TipRanks.com)
- News Sentiment for BMRN stock: Neutral
- Blogger Consensus for BMRN stock: Bullish
- Media Buzz for BMRN stock: Low
- Insider Signal for BMRN stock: Very Negative
- Investor Sentiment for BMRN stock: Negative
- Hedge Fund signal for BMRN stock: Very Positive
The stock market is extremely volatile, and you need to do your own research on BMRN stock including scouring the social networks like BMRN StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for BMRN stock chart >>
Summary: Moderna, Inc. is a clinical-stage pharmaceutical company, primarily focused on discovering and developing messenger RNA (mRNA) based therapies. The company's mRNA based COVID-19 vaccine, Spikevax (mRNA-1273), is approved for use in adults in the United States. The vaccine is also authorized for emergency use in several countries as COVID-19 vaccine. The company has also developed booster doses of its COVID-19 vaccine and is developing variant-specific booster candidates.
- Recent MRNA Stock Price: $112.81
- Yearly Gain for MRNA stock: -22.10%
- Market Cap for MRNA stock: $41.33B
- P/E Ratio for MRNA stock: 39.896
Will MRNA's stock price go up? Is there an accurate MRNA stock forecast available?
TipRanks.com reports that Moderna currently has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $159.60. The target pricing ranges from a high MRNA forecast of $210 down to a low forecast of $123. Moderna (MRNA)’s last closing stock price was $112.81 which would put the average price target at 47.37% upside.
In addition, TradingView issued a buy rating for MRNA stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Bearish short-term outlook. Remember, securities are volatile, so please do your own research on MRNA stock.
Other analysts covering MRNA include:
- Gena Wang of Barclays issued a Buy rating with the price target of $210 on 21 hours ago
- Michael Yee of Jefferies issued a Buy rating with the price target of $175 on 21 hours ago
- Geoff Meacham of Bank of America Securities issued a Hold rating with the price target of $150 on 1 day ago
- Jasper Hellweg of Argus Research issued a Buy rating with the price target of $140 on 1 day ago
If you are wondering if MRNA is a good stock to buy, here are 3rd party ratings for MRNA stock:
- TipRanks.com: Moderate Buy
- TradingView.com: buy
- Yahoo! Finance: Bearish Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: Hold, Top 40% (101 out of 252)
What is the sentiment on the street regarding Moderna? (Current ratings compiled by TipRanks.com)
- News Sentiment for MRNA stock: Very Bullish
- Blogger Consensus for MRNA stock: Bullish
- Media Buzz for MRNA stock: Very High
- Insider Signal for MRNA stock: ―
- Investor Sentiment for MRNA stock: Very Negative
- Hedge Fund signal for MRNA stock: Positive
The stock market is extremely volatile, and you need to do your own research on MRNA stock including scouring the social networks like MRNA StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for MRNA stock chart >>
Summary: AstraZeneca PLC was incorporated in England and Wales on 17 June 1992. From February 1993 until April 1999, the Company was called Zeneca Group PLC. On 6 April 1999, the Company changed its name to AstraZeneca PLC. It is a biopharmaceutical company. The Company focuses on three important areas of healthcare: Cardiovascular and Metabolic disease (CVMD); Oncology; and Respiratory, Inflammation and Autoimmunity (RIA). The Company is also engaged in the Infection, Neuroscience and Gastrointestinal (ING) disease areas. It operates in more than 100 countries.
- Recent AZNCF Stock Price: $133.00
- Yearly Gain for AZNCF stock: 6.42%
- Market Cap for AZNCF stock: $204.92B
- P/E Ratio for AZNCF stock: 32.144
Will AZNCF's stock price go up? Is there an accurate AZNCF stock forecast available?
TipRanks.com reports that AstraZeneca currently has 5 analysts offering 12-month price targets and the consensus is a Moderate Buy rating with an average price target is $173.40. The target pricing ranges from a high AZNCF forecast of $196.63 down to a low forecast of $137.44. AstraZeneca (AZNCF)’s last closing stock price was $133.00 which would put the average price target at 29.72% upside.
In addition, TradingView issued a sell rating for AZNCF stock over the next month, Barchart.com has a Strong sell rating and Yahoo! Finance has a Neutral short-term outlook. Remember, securities are volatile, so please do your own research on AZNCF stock.
Other analysts covering AZNCF include:
- Emmanuel Papadakis of Deutsche Bank issued a Hold rating with the price target of $137.44 on 2 days ago
- Andrew Baum of Citi issued a Buy rating with the price target of $174.92 on 3 days ago
- Emily Field of Barclays issued a Buy rating with the price target of $183.07 on 3 days ago
- James Gordon of J.P. Morgan issued a Buy rating with the price target of $174.92 on 3 days ago
If you are wondering if AZNCF is a good stock to buy, here are 3rd party ratings for AZNCF stock:
- TipRanks.com: Moderate Buy
- TradingView.com: sell
- Yahoo! Finance: Neutral Short-Term Outlook
- Barchart.com: Strong sell
- Zacks.com: n/a, n/a
What is the sentiment on the street regarding AstraZeneca? (Current ratings compiled by TipRanks.com)
- News Sentiment for AZNCF stock: Neutral
- Blogger Consensus for AZNCF stock: ―
- Media Buzz for AZNCF stock: Very Low
- Insider Signal for AZNCF stock: ―
- Investor Sentiment for AZNCF stock: Very Positive
- Hedge Fund signal for AZNCF stock: No Signal
The stock market is extremely volatile, and you need to do your own research on AZNCF stock including scouring the social networks like AZNCF StockTwits, Twitter and Reddit before you decide to make any investment.
Click here for AZNCF stock chart >>
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. TipRanks.com tracks and measures the performance of over 50,000 financial experts. The TipRanks Star Ranking TM is calculated based on expert success rate, average return and statistical significance. Get more from TipRanks.com here >>
The Editor, HealthTechMovers.com
HealthTechMovers.com (HTM) is built for investors who are interested in healthcare stocks, health insurance stocks, healthcare technology stocks, biotechnology stocks, pharmaceutical stocks, healthcare service provider stocks, life science stocks and more. HTM aggregates market data from top tier financial content providers like Barchart.com, Tipranks.com, TradingView.com, Yahoo! Finance, and Zacks.com. The research and editorial team behind HTM consolidates this aggregated data into easily consumable reports used to produce articles, newsletters, and web content. The reports produced by HTM contain timely information stock analysis, stock price targets, earnings announcements, insider trades, dividends, and top moving stocks.
==============================================================================
